History

SynAct Pharma ApS was formed in 2012. SynAct Pharma AB, the group’s parent company, was formed in April 2016.

2012

  • Synact Pharma ApS is formed and starts its operations based on intellectual property rights and assets acquired from Action Pharma after Action Pharma’s biggest asset, AP214, was sold to AbbVie.

2013

  • Pharmacological studies with candidate drug AP1189 begin in collaboration with the William Harvey Research Institute (WHRI), London

2014

  • Characterisation of AP1189 begins on the basis of pharmacological, metabolic and manufacturing engineering aspects.

2015

  • Pre-clinical studies with AP1189 are discontinued.
  • Scientific article regarding “Mode of Action” for AP1189 is published.
  • Patents are approved in Europe (patents in the US were approved in 2011).

2016

  • SynAct Pharma AB was formed and listed on AktieTorget in July 2016.
  • Production of pharmaceutical substance and pharmaceutical products for clinical phase I are finalised
  • The application to initiate Clinical Phase I study with AP1189 is submitted

2017

  • Start of Phase I clinical study with AP1189.
  • Start of preparation for Phase II clinical study with AP1189 in psoriatic arthritis.
  • Initiated pre-clinical studies in other indications

2018

  • Financing of 22,4 m SEK
    • Filling of additional patent applications

2019

  • Positive preliminary data from phase I clinical study identifying doses for clinical phase II with AP1189.
    • Initiation of Phase ll sudy in RA
    • BD activitities initiated